The application of direct viral cytopathic hypothesis to design drug trials in the battle against COVID-19

COVID-19 has caused many deaths worldwide. Systemic complications alongside coagulopathy, and ARDS account for the majority of COVID-19 mortalities. The pathogenesis of the disease can be explained by two theories of direct viral cytopathy and systemic inflammatory cascade of events. ACE-2 is shown...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashraf, Mohammad Ali, Sherafat, Alireza, Pourdast, Alieh, Nazemi, Pershang, Mohraz, Minoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429091/
https://www.ncbi.nlm.nih.gov/pubmed/32803688
http://dx.doi.org/10.1007/s40199-020-00368-3
_version_ 1783571220169490432
author Ashraf, Mohammad Ali
Sherafat, Alireza
Pourdast, Alieh
Nazemi, Pershang
Mohraz, Minoo
author_facet Ashraf, Mohammad Ali
Sherafat, Alireza
Pourdast, Alieh
Nazemi, Pershang
Mohraz, Minoo
author_sort Ashraf, Mohammad Ali
collection PubMed
description COVID-19 has caused many deaths worldwide. Systemic complications alongside coagulopathy, and ARDS account for the majority of COVID-19 mortalities. The pathogenesis of the disease can be explained by two theories of direct viral cytopathy and systemic inflammatory cascade of events. ACE-2 is shown to be the cellular host receptor for SARS-CoV-2. It might be the key to explain the pathogenesis of systemic complications with a focus on the direct viral cytopathic hypothesis. Different medications tend to show up in many in vitro drug screens. However, more trials are needed to translate their application into in vivo efficacy.
format Online
Article
Text
id pubmed-7429091
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-74290912020-08-17 The application of direct viral cytopathic hypothesis to design drug trials in the battle against COVID-19 Ashraf, Mohammad Ali Sherafat, Alireza Pourdast, Alieh Nazemi, Pershang Mohraz, Minoo Daru Letter to the Editor COVID-19 has caused many deaths worldwide. Systemic complications alongside coagulopathy, and ARDS account for the majority of COVID-19 mortalities. The pathogenesis of the disease can be explained by two theories of direct viral cytopathy and systemic inflammatory cascade of events. ACE-2 is shown to be the cellular host receptor for SARS-CoV-2. It might be the key to explain the pathogenesis of systemic complications with a focus on the direct viral cytopathic hypothesis. Different medications tend to show up in many in vitro drug screens. However, more trials are needed to translate their application into in vivo efficacy. Springer International Publishing 2020-08-15 /pmc/articles/PMC7429091/ /pubmed/32803688 http://dx.doi.org/10.1007/s40199-020-00368-3 Text en © Springer Nature Switzerland AG 2020
spellingShingle Letter to the Editor
Ashraf, Mohammad Ali
Sherafat, Alireza
Pourdast, Alieh
Nazemi, Pershang
Mohraz, Minoo
The application of direct viral cytopathic hypothesis to design drug trials in the battle against COVID-19
title The application of direct viral cytopathic hypothesis to design drug trials in the battle against COVID-19
title_full The application of direct viral cytopathic hypothesis to design drug trials in the battle against COVID-19
title_fullStr The application of direct viral cytopathic hypothesis to design drug trials in the battle against COVID-19
title_full_unstemmed The application of direct viral cytopathic hypothesis to design drug trials in the battle against COVID-19
title_short The application of direct viral cytopathic hypothesis to design drug trials in the battle against COVID-19
title_sort application of direct viral cytopathic hypothesis to design drug trials in the battle against covid-19
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429091/
https://www.ncbi.nlm.nih.gov/pubmed/32803688
http://dx.doi.org/10.1007/s40199-020-00368-3
work_keys_str_mv AT ashrafmohammadali theapplicationofdirectviralcytopathichypothesistodesigndrugtrialsinthebattleagainstcovid19
AT sherafatalireza theapplicationofdirectviralcytopathichypothesistodesigndrugtrialsinthebattleagainstcovid19
AT pourdastalieh theapplicationofdirectviralcytopathichypothesistodesigndrugtrialsinthebattleagainstcovid19
AT nazemipershang theapplicationofdirectviralcytopathichypothesistodesigndrugtrialsinthebattleagainstcovid19
AT mohrazminoo theapplicationofdirectviralcytopathichypothesistodesigndrugtrialsinthebattleagainstcovid19
AT ashrafmohammadali applicationofdirectviralcytopathichypothesistodesigndrugtrialsinthebattleagainstcovid19
AT sherafatalireza applicationofdirectviralcytopathichypothesistodesigndrugtrialsinthebattleagainstcovid19
AT pourdastalieh applicationofdirectviralcytopathichypothesistodesigndrugtrialsinthebattleagainstcovid19
AT nazemipershang applicationofdirectviralcytopathichypothesistodesigndrugtrialsinthebattleagainstcovid19
AT mohrazminoo applicationofdirectviralcytopathichypothesistodesigndrugtrialsinthebattleagainstcovid19

Ejemplares similares